Danny H Sugimoto (Danny Sugimoto)

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 8

Top Topics

Glycemic Control

Platelet Rich Plasma

Top Venues

Diabetes, obesity & metabolism

Postgraduate medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Elena A Christofides, Orlando Puente, Paul Norwood, Douglas Denham, Hiralal Maheshwari, Michael Lillestol, Terence Hart, Samer Nakhle, Anurekha Chadha, David Fitz-Patrick, Danny H Sugimoto, Joseph Soufer, Douglas Young, Mark L Warren, David Huffman, John Reed, Harold Bays, Samir Arora, Barbara Rizzardi, Raymond Tidman, Marc Rendell, Kimball A Johnson
Immunogenicity, efficacy, and safety of biosimilar insulin glargine (Gan & Lee glargine) compared with originator insulin glargine (Lantus®) in patients with type 2 diabetes after 26 weeks' treatment: A randomized open label study. Diabetes, obesity & metabolism 26 (6) (2024)
Elena A Christofides, Orlando Puente, Paul Norwood, Douglas Denham, Hiralal Maheshwari, Michael Lillestol, Terence Hart, Samer Nakhle, Anurekha Chadha, David Fitz-Patrick, Danny H Sugimoto, Joseph Soufer, Douglas Young, Mark L Warren, David Huffman, John Reed, Harold Bays, Samir Arora, Barbara Rizzardi, Raymond Tidman, Marc Rendell, Kimball A Johnson
Immunogenicity, efficacy, and safety of biosimilar insulin glargine (Gan & Lee glargine) compared with originator insulin glargine (Lantus®) in patients with type 2 diabetes after 26 weeks' treatment: A randomized open label study. Diabetes, obesity & metabolism (2024)
Elena A Christofides, Orlando Puente, Paul Norwood, Douglas Denham, Hiralal Maheshwari, Michael Lillestol, Terence Hart, Samer Nakhle, Anurekha Chadha, David Fitz-Patrick, Danny H Sugimoto, Joseph Soufer, Douglas Young, Mark L Warren, David Huffman, John Reed, Harold Bays, Samir Arora, Barbara Rizzardi, Raymond Tidman, Marc Rendell, Kimball A Johnson
Immunogenicity, efficacy, and safety of biosimilar insulin glargine (Gan & Lee glargine) compared with originator insulin glargine (Lantus®) in patients with type 2 diabetes after 26 weeks' treatment: A randomized open label study. Diabetes, obesity & metabolism 26 (6) (2024)
Anastassia Amaro, Neil S Skolnik, Danny H Sugimoto
Cardiometabolic risk factors efficacy of semaglutide in the STEP program. Postgraduate medicine 134 (sup1) (2023)
Anastassia Amaro, Neil S Skolnik, Danny H Sugimoto
Cardiometabolic risk factors efficacy of semaglutide in the STEP program. Postgraduate medicine 134 (sup1) (2023)
Anastassia Amaro, Danny H Sugimoto, Sean Wharton
Efficacy and safety of semaglutide for weight management: evidence from the STEP program. Postgraduate medicine 134 (sup1) (2023)
Eden M Miller, Ankur Doshi, Randi Grøn, Esteban Jódar, Petra Őrsy, Mattis F Ranthe, Danny H Sugimoto, Nikolaos Tentolouris, Adie Viljoen, Liana K Billings
IDegLira improves patient-reported outcomes while using a simple regimen with fewer injections and dose adjustments compared with basal-bolus therapy. Diabetes, obesity & metabolism 21 (12) (2019)
Danny H Sugimoto, Terry Dex, William Stager, Vanita R Aroda
Efficacy of iGlarLixi, a fixed-ratio combination of insulin glargine and lixisenatide, in patients with type 2 diabetes stratified as at high or low risk according to HEDIS measurements. Diabetes, obesity & metabolism 20 (11) (2018)